Mirabella (Ethinylestradiol, Levonorgestrel)

The estrogen component (ethinylestradiol) and the progestin component (levonorgestrel) work together to suppress the hypothalamic‑pituitary‑ovarian axis, preventing the surge of luteinizing hormone that triggers ovulation. Additionally, levonorgestrel thickens cervical mucus and modifies the endometrium, creating conditions that are unfavorable for fertilisation and implantation.

The dosing regimen for Mirabella is determined by the prescribing healthcare professional. Typically, it is taken as a daily tablet according to a specific cycle, but the exact schedule and any missed‑dose instructions should be provided by the prescriber.

Mirabella is intended for use only when a woman is not pregnant. If pregnancy occurs, the product should be discontinued immediately. While limited data exist for breastfeeding, most guidelines advise caution and suggest discussing alternative contraception with a healthcare provider.

To request Mirabella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabella contains the standard dose combination of ethinylestradiol and levonorgestrel, which is comparable to many other combined oral contraceptives on the market. Its efficacy, safety profile and side‑effect spectrum are similar to other products that use the same active ingredients, though individual tolerability may vary.

Mirabella tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Mirabella is taken orally, usually once daily at the same time each day. The tablets are swallowed whole with water and should be started according to the prescriber’s instructions, often on the first day of the menstrual period or as part of a prescribed cycle.

Serious but rare risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial events such as stroke or myocardial infarction, severe allergic reactions, and liver disorders. Patients should seek immediate medical attention if they experience symptoms like sudden leg pain, chest pain, severe headache, or jaundice.

Mirabella is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking medications that significantly reduce its effectiveness.